Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.

Abstract excerpt

BACKGROUND: The genomic knowledge on urothelial carcinoma is expanding. It is recognised that urothelial carcinoma is a disease with a high somatic mutation rate and a high prevalence of genetic alterations, as discussed by Thomas and Sonpavde (2022). In the context of a disease rich with somatic alterations, continuing efforts to better identify which patients may benefit most from targeted therapy,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma, Transitional Cell
• Share to Class I Phosphatidylinositol 3-Kinases